Publikationen, an denen er mitarbeitet Luis Sierrasesúmaga Ariznavarreta (45)

2017

  1. Ionizing radiation received by patients with osteosarcoma during intra-arterial chemotherapy treatment

    Anales del sistema sanitario de Navarra, Vol. 40, Núm. 1, pp. 85-92

2016

  1. Consequences of Delayed Diagnosis

    Cañadell's Pediatric Bone Sarcomas (Springer), pp. 139-146

2015

  1. A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma

    Cancer Discovery, Vol. 5, Núm. 9, pp. 920-931

  2. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

    Journal of the National Cancer Institute, Vol. 107, Núm. 12

  3. Germline TP53 Variants and Susceptibility to Osteosarcoma

    Journal of the National Cancer Institute, Vol. 107, Núm. 7

  4. Lipid nanoparticles enhance the efficacy of chemotherapy in primary and metastatic human osteosarcoma cells

    Journal of Drug Delivery Science and Technology, Vol. 30, pp. 435-442

2014

  1. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

    Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633

  2. The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity

    Journal of Bone and Mineral Research, Vol. 29, Núm. 10, pp. 2287-2296

2013

  1. Genome-wide association study identifies two susceptibility loci for osteosarcoma

    Nature Genetics, Vol. 45, Núm. 7, pp. 799-803

2012

  1. Cortactin (CTTN) overexpression in osteosarcoma correlates with advanced stage and reduced survival

    Cancer Biomarkers, Vol. 10, Núm. 1, pp. 35-41

  2. Unexpected diagnosis in the case of a 16-year-old boy with back pain

    Medicina Clinica, Vol. 139, Núm. 6

2011

  1. Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: A pharmacogenetic study

    PLoS ONE, Vol. 6, Núm. 10

2009

  1. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients

    Pharmacogenomics Journal, Vol. 9, Núm. 5, pp. 347-353

  2. Methotrexate in Pediatric Osteosarcoma: Response and Toxicity in Relation to Genetic Polymorphisms and Dihydrofolate Reductase and Reduced Folate Carrier 1 Expression

    Journal of Pediatrics, Vol. 154, Núm. 5, pp. 688-693

  3. Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis

    Clinical Cancer Research, Vol. 15, Núm. 16, pp. 5082-5091

  4. Prognostic factors and outcomes for osteosarcoma: An international collaboration

    European Journal of Cancer, Vol. 45, Núm. 13, pp. 2367-2375

  5. Proteomic analysis of chemonaïve pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets

    Journal of Proteome Research, Vol. 8, Núm. 8, pp. 3882-3888

2008

  1. CDH11 expression is associated with survival in patients with osteosarcoma

    Cancer Genomics and Proteomics, Vol. 5, Núm. 1, pp. 37-42

  2. Determinación y validación de dianas implicadas en la carcinogénesis del osteosarcoma infantil mediante plataformas de genómica y proteómica

    Proteómica: revista de la Sociedad Española de Proteómica, Núm. 1, pp. 106-106

  3. The genetic contribution to first psychotic episodes in children and adolescents of the child and adolescent first-episode psychosis study

    Psychiatric Genetics, Vol. 18, Núm. 3, pp. 151-152